Skip to content

Search

Showing results for "1"

Circulating Soluble Factors and T-Cell Subsets as Immunological Predictors of Therapy Response in Human Cutaneous Leishmaniasis

Human cutaneous leishmaniasis, a neglected tropical disease caused by Leishmania braziliensis, presents treatment challenges due to varying therapeutic responses. Current therapies often encounter limited efficacy and treatment failure, demanding a deeper understanding of immunopathogenesis and predictive markers.

National Carers Week

We recently celebrated National Carers Week! A time to recognise and raise awareness for the more than 3 million Australians who provide care to a family member or a friend.

Looking at the Big Food Picture For T1D

Kids with diabetes should think beyond just carbs, according to The Kids Research Institute Australia senior dietitian Dr Amelia Harray.

April lives life in the fast lane

April Welsh lives life in top gear, literally. Diagnosed with T1D just before her 4th birthday, April became the first female to race in the Formula Vee

Lucia's journey

Meet 11-year-old Lucia, who was diagnosed with Type 1 Diabetes when she was 10. Read all about her journey and how she manages her disease in her own words.

PACT training

Find out more about Paediatric Autism Communication Therapy training for allied health and autism professionals at CliniKids.

Talking to your child about their autism diagnosis

In this blog, Speech Pathology Lead Aria May explores how to talk to your child about a recent autism diagnosis.

Targeting intolerance of uncertainty in young children diagnosed with autism: A randomized controlled trial of a parent-mediated group intervention

Young children diagnosed with autism experience high rates of co-occurring anxiety, with uncertainty-related concerns commonly reported. This randomized controlled trial investigated an 8-week parent-mediated group anxiety intervention, “Coping with Uncertainty in Everyday Situations” (CUES-Junior©).

Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade

Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4, programmed cell death protein/ligand 1 are approved for treatment of multiple cancer types.